<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>378</serviceExecutionTime><Drug id="51044"><DrugName>beraprost sodium (oral sustained release), Toray/Astellas/Lung Rx</DrugName><DrugNamesKey><Name id="42923315">Berasus LA</Name><Name id="42923316">Careload LA</Name><Name id="42757901">beraprost</Name><Name id="42757902">beraprost sodium</Name></DrugNamesKey><DrugSynonyms><Name><Value>beraprost</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>beraprost sodium</Value><Types><Type>USAN</Type></Types></Name><Name><Value>beraprost SR</Value></Name><Name><Value>beraprost (oral sustained release), Toray/Astellas/Lung Rx</Value></Name><Name><Value>beraprost MR</Value></Name><Name><Value>YM-533</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Berasus LA</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Careload LA</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>beraprost sodium (oral sustained release), Toray/Astellas/Lung Rx</Value></Name><Name><Value>TRK-100STP</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BPS-MR</Value></Name><Name><Value>88430-50-6</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>88475-69-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20406">Toray Industries Inc</CompanyOriginator><CompaniesPrimary><Company id="17633">Kaken Pharmaceutical Co Ltd</Company><Company id="1013295">Astellas Pharma Inc</Company><Company id="20406">Toray Industries Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1023357">Lung Biotechnology Inc</Company><Company id="25439">United Therapeutics Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1013295" type="Company"><TargetEntity id="4295876965" type="organizationId">Astellas Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="1023357" type="Company"><TargetEntity id="5000209501" type="organizationId">Lung Biotechnology Inc</TargetEntity></SourceEntity><SourceEntity id="17633" type="Company"><TargetEntity id="4295878524" type="organizationId">Kaken Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="20406" type="Company"><TargetEntity id="4295877338" type="organizationId">Toray Industries Inc</TargetEntity></SourceEntity><SourceEntity id="25439" type="Company"><TargetEntity id="4295915261" type="organizationId">United Therapeutics Corp</TargetEntity></SourceEntity><SourceEntity id="1867" type="ciIndication"><TargetEntity id="10037400" type="MEDDRA"></TargetEntity><TargetEntity id="D006976" type="MeSH"></TargetEntity><TargetEntity id="-104458654" type="omicsDisease"></TargetEntity><TargetEntity id="243" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="260" type="ciIndication"><TargetEntity id="10034636" type="MEDDRA"></TargetEntity><TargetEntity id="D016491" type="MeSH"></TargetEntity><TargetEntity id="-817414410" type="omicsDisease"></TargetEntity><TargetEntity id="260" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3137" type="ciIndication"><TargetEntity id="M48.0" type="ICD10"></TargetEntity><TargetEntity id="10041540" type="MEDDRA"></TargetEntity><TargetEntity id="D013130" type="MeSH"></TargetEntity><TargetEntity id="-286867296" type="omicsDisease"></TargetEntity><TargetEntity id="1177" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="69" type="ciIndication"><TargetEntity id="10038435" type="MEDDRA"></TargetEntity><TargetEntity id="346" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="327" type="Action"><TargetEntity id="297" type="Mechanism">Prostacyclin Analogs</TargetEntity></SourceEntity><SourceEntity id="312" type="Action"><TargetEntity id="3554" type="Mechanism">Platelet Adhesion Inhibitors</TargetEntity><TargetEntity id="3985" type="Mechanism">Drugs Targeting on PolyQ-expanded Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Pulmonary hypertension - Japan - Dec-2007</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1867">Pulmonary hypertension</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="260">Peripheral vascular disease</Indication><Indication id="3137">Spinal stenosis</Indication><Indication id="69">Renal failure</Indication></IndicationsSecondary><ActionsPrimary><Action id="327">PGI2 agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2657">Antihypertensive</Action><Action id="312">Platelet aggregation inhibitor</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="660">Oral sustained release formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>B1C</Code><Name>PLATELET AGGREGATION INHIBITORS</Name></Ephmra><Ephmra><Code>C2</Code><Name>ANTIHYPERTENSIVES</Name></Ephmra></EphmraCodes><LastModificationDate>2019-04-03T02:02:38.000Z</LastModificationDate><ChangeDateLast>2016-06-08T00:00:00.000Z</ChangeDateLast><AddedDate>2004-08-31T11:52:40.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="20406" linkType="Company"&gt;Toray&lt;/ulink&gt; has developed and  launched Careload LA (BPS-MR; YM-533), a  sustained-release oral &lt;ulink linkID="5943" linkType="Drug"&gt;beraprost sodium&lt;/ulink&gt; tablet, for the  treatment of pulmonary arterial hypertension (PAH). In December 2007, Toray  launched the product in Japan with licensee &lt;ulink linkID="1013295" linkType="Company"&gt;Astellas&lt;/ulink&gt;; &lt;ulink linkID="17633" linkType="Company"&gt;Kaken&lt;/ulink&gt; launched an identical product at the same time [&lt;ulink linkID="862584" linkType="Reference"&gt;862584&lt;/ulink&gt;], [&lt;ulink linkID="1465909" linkType="Reference"&gt;1465909&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Toray and Astellas were also developing the formulation for the potential treatment of renal failure [&lt;ulink linkID="644856" linkType="Reference"&gt;644856&lt;/ulink&gt;]. In November 2009, phase III trials were underway in Japan/Asia [&lt;ulink linkID="1055156" linkType="Reference"&gt;1055156&lt;/ulink&gt;]; in May 2011, phase II/III trials were  ongoing in Japan/Asia [&lt;ulink linkID="1196517" linkType="Reference"&gt;1196517&lt;/ulink&gt;]. In February 2015, the drug was listed as being in phase III for chronic renal failure  in Japan and Asia [&lt;ulink linkID="1630716" linkType="Reference"&gt;1630716&lt;/ulink&gt;]. However, in July 2015, Astellas stated that development was discontinued because the phase IIb/III results were insufficient for filing [&lt;ulink linkID="1683137" linkType="Reference"&gt;1683137&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Toray was previously developing the drug for peripheral vascular disease (PVD). By  March 2004, Toray was conducting phase I trials in Japan for  PVD [&lt;ulink linkID="530382" linkType="Reference"&gt;530382&lt;/ulink&gt;]. However, no further development was reported for the indication.  Toray and Kaken were jointly developing the sustained-release formulation for the potential treatment of lumbal spinal canal stenosis. In July 2010, development was ongoing [&lt;ulink linkID="1229604" linkType="Reference"&gt;1229604&lt;/ulink&gt;]; this was still the case in October 2011 [&lt;ulink linkID="1229535" linkType="Reference"&gt;1229535&lt;/ulink&gt;]. However, no further development was reported since then.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="25439" linkType="Company"&gt;United Therapeutics&lt;/ulink&gt; and its subsidiary &lt;ulink linkID="1023357" linkType="Company"&gt;Lung LLC&lt;/ulink&gt; (now Lung Biotechnology, formerly Lung Rx) were previously also developing the drug, under license from Toray, for vascular and cardiovascular indications  [&lt;ulink linkID="372762" linkType="Reference"&gt;372762&lt;/ulink&gt;], [&lt;ulink linkID="555605" linkType="Reference"&gt;555605&lt;/ulink&gt;], [&lt;ulink linkID="1275139" linkType="Reference"&gt;1275139&lt;/ulink&gt;]. By the end of 2000, United Therapeutics began phase I trials for PVD in the US and Canada [&lt;ulink linkID="412483" linkType="Reference"&gt;412483&lt;/ulink&gt;]. In March 2007, United Therapeutics discontinued development of the drug and its wholly owned subsidiary, Lung Rx, took over the license [&lt;ulink linkID="778492" linkType="Reference"&gt;778492&lt;/ulink&gt;]; however no further development was reported by Lung Rx for PVD. &lt;ulink linkID="1023357" linkType="Company"&gt;&lt;/ulink&gt;In January 2009, Lung Rx listed the program as being in phase II for PAH     [&lt;ulink linkID="979320" linkType="Reference"&gt;979320&lt;/ulink&gt;]. In November 2011, United Therapeutics reported that a phase II trial of modified-release beraprost (beraprost-MR) did not provide data supporting efficacy using a twice-daily dosing regimen;  however, the results suggested that efficacy may be improved by providing more stable plasma concentrations of beraprost. By that time, Lung Rx had initiated development of a modified-release formulation of the S-isomer &lt;ulink linkID="79742" linkType="Drug"&gt;esuberaprost sodium&lt;/ulink&gt; (BPS-314d-MR) [&lt;ulink linkID="1311512" linkType="Reference"&gt;1311512&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In December 2011, the FDA awarded the drug Orphan status for PAH [&lt;ulink linkID="1264403" linkType="Reference"&gt;1264403&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In May 2008, the COMP of the EMEA recommended the drug be granted Orphan status for PAH [&lt;ulink linkID="907761" linkType="Reference"&gt;907761&lt;/ulink&gt;]. In July 2008, the product was granted Orphan Drug status for PAH [&lt;ulink linkID="943143" linkType="Reference"&gt;943143&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;The drug was approved in Japan for PAH in October 2007, after being submitted for approval in September 2006 and granted a priority review in February 2007. The drug was to be marketed by Toray and Astellas [&lt;ulink linkID="842148" linkType="Reference"&gt;842148&lt;/ulink&gt;]. The drug was launched in Japan in December 2007 [&lt;ulink linkID="862584" linkType="Reference"&gt;862584&lt;/ulink&gt;]. In May 2010, Astellas expected approval in Japan by fiscal 2014 [&lt;ulink linkID="1102975" linkType="Reference"&gt;1102975&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In March 2019, the product was granted "Clinically Urgent Foreign Drug" in China [&lt;ulink linkID="2135932" linkType="Reference"&gt;2135932&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;South Asia&lt;/subtitle&gt;In May 2010, Astellas expected approval in Asia by fiscal 2014 [&lt;ulink linkID="1102975" linkType="Reference"&gt;1102975&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Renal failure&lt;/subtitle&gt;In March 2010, a randomized, double blind phase IIb/III trial (&lt;ulink linkID="65018" linkType="Protocol"&gt;NCT01090037&lt;/ulink&gt;, 100CRS02/533-CL-003, CTR20131825) was initiated in chronic renal failure patients with primary glomerular disease or nephrosclerosis (n = 892, China n = 200) in Hong Kong, Japan, South Korea, Malaysia, Taiwan, Thailand. The trial was conducted to assess the safety, confirm the superiority over placebo, and determine the recommended therapeutic dose in the 2 doses of TRK-100STP  [&lt;ulink linkID="1289192" linkType="Reference"&gt;1289192&lt;/ulink&gt;]. In June 2011, the trial was initiated in China [&lt;ulink linkID="1581424" linkType="Reference"&gt;1581424&lt;/ulink&gt;]. By March 2014, recruitment was completed in China and other sites [&lt;ulink linkID="1289192" linkType="Reference"&gt;1289192&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2010, an application for confirmatory trial was filed in China; in February 2011, review of the application was concluded [&lt;ulink linkID="1581429" linkType="Reference"&gt;1581429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2009, the formulation was in phase III trials in Japan/Asia [&lt;ulink linkID="1055156" linkType="Reference"&gt;1055156&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2005, a randomized, double-blind, parallel assigned phase II trial (&lt;ulink linkID="233191" linkType="Protocol"&gt;NCT02480751&lt;/ulink&gt;;100CRS01/533-CL-00) in Japanese patients ( n = 113) with chronic renal failure (primary glomerular disease/nephrosclerosis)  was initiated to assess the safety and efficacy of TRK-100STP. In May 2008, the trial was completed [&lt;ulink linkID="1674658" linkType="Reference"&gt;1674658&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2005, it was in phase II studies in Japan for chronic renal failure [&lt;ulink linkID="644856" linkType="Reference"&gt;644856&lt;/ulink&gt;]. In August 2008, phase II trials were still ongoing [&lt;ulink linkID="936805" linkType="Reference"&gt;936805&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;PAH&lt;/subtitle&gt;In November 2011, United Therapeutics reported that a phase II trial of beraprost-MR did not provide data supporting efficacy using a twice-daily dosing regimen. The results suggested that efficacy may be improved by providing more stable plasma concentrations of beraprost, leading to increased therapeutic exposure [&lt;ulink linkID="1311512" linkType="Reference"&gt;1311512&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2008, Lung Rx planned an open-label, dose finding, phase II trial (&lt;ulink linkID="32501" linkType="Protocol"&gt;NCT00781885&lt;/ulink&gt;; BPS-MR-PAH-201), of beraprost modified release tablets (60 microg, bid to 600 microg, bid), taken until    MTD, in patients (n = 10), with pulmonary arterial hypertension. At that time, the study was expected to begin in January 2009, with an estimated completion date in June 2009 [&lt;ulink linkID="979329" linkType="Reference"&gt;979329&lt;/ulink&gt;]. In November 2008, Lung Rx planned an extension to the phase II trial (&lt;ulink linkID="36236" linkType="Protocol"&gt;NCT00792571&lt;/ulink&gt;; BPS-MR-PAH-202). In the study, patients (n = 10), were to continue treatment with beraprost for one year [&lt;ulink linkID="979330" linkType="Reference"&gt;979330&lt;/ulink&gt;]. In January 2009, Lung Rx listed the program as in phase II     [&lt;ulink linkID="979320" linkType="Reference"&gt;979320&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In May 2016, preclinical data were presented at the 2016 ATS International Conference in San Francisco, CA. In HEK-239-IP cells, EC50 for cAMP generation was 15.8, 10.4 and 0.4 nM for BPS-315d, beraprost and   BPS-314d, respectively [&lt;ulink linkID="1767907" linkType="Reference"&gt;1767907&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2002, preclinical data were published showing that oral beraprost, given twice daily at 30, 100 or 300 mg/kg to rats in the late stage of nephritis when renal dysfunction was evident, inhibited increases in markers of renal function deterioration [&lt;ulink linkID="646009" linkType="Reference"&gt;646009&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In October 2007, &lt;ulink linkID="17633" linkType="Company"&gt;Kaken Pharmaceuticals&lt;/ulink&gt; had marketing rights to Careload LA in Japan   [&lt;ulink linkID="898564" linkType="Reference"&gt;898564&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2000, United Therapeutics obtained from Toray the exclusive right to develop and market beraprost SR in the US and Canada  for all vascular and cardiovascular diseases [&lt;ulink linkID="372762" linkType="Reference"&gt;372762&lt;/ulink&gt;], [&lt;ulink linkID="555605" linkType="Reference"&gt;555605&lt;/ulink&gt;]. In March 2007, United Therapeutics' wholly owned subsidiary, Lung Rx, took over the agreement with Toray. At that time, Toray hoped to deliver drug documentation and clinical trial data to Lung Rx,  before the end of 2007 [&lt;ulink linkID="778492" linkType="Reference"&gt;778492&lt;/ulink&gt;]. By May 2007, the agreement was expanded to include Europe [&lt;ulink linkID="789051" linkType="Reference"&gt;789051&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2004, Toray had filed &lt;ulink linkID="IN2740542" linkType="Patent"&gt;WO-0067748&lt;/ulink&gt; and &lt;ulink linkID="PA2916988" linkType="Patent"&gt;WO-2004098611&lt;/ulink&gt; claiming use of beraprost and other prostacyclin analogs in kidney failure.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20406">Toray Industries Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-19T00:00:00.000Z</StatusDate><Source id="862584" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17633">Kaken Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-19T00:00:00.000Z</StatusDate><Source id="862584" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-19T00:00:00.000Z</StatusDate><Source id="862584" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20406">Toray Industries Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2019-03-28T00:00:00.000Z</StatusDate><Source id="2135932" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20406">Toray Industries Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-05T00:00:00.000Z</StatusDate><Source id="1683137" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-05T00:00:00.000Z</StatusDate><Source id="1683137" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20406">Toray Industries Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-08T00:00:00.000Z</StatusDate><Source id="1683137" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20406">Toray Industries Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-05T00:00:00.000Z</StatusDate><Source id="1683137" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-06-02T00:00:00.000Z</StatusDate><Source id="1683137" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-08T00:00:00.000Z</StatusDate><Source id="1683137" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-05T00:00:00.000Z</StatusDate><Source id="1683137" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20406">Toray Industries Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-06-02T00:00:00.000Z</StatusDate><Source id="1683137" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20406">Toray Industries Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3137">Spinal stenosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-08-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20406">Toray Industries Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="260">Peripheral vascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-09-12T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1023357">Lung Biotechnology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="260">Peripheral vascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17633">Kaken Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3137">Spinal stenosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-08-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1023357">Lung Biotechnology Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="260">Peripheral vascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1023357">Lung Biotechnology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20406">Toray Industries Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-10-31T00:00:00.000Z</StatusDate><Source id="1674658" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-10-31T00:00:00.000Z</StatusDate><Source id="1674658" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20406">Toray Industries Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-08-02T00:00:00.000Z</StatusDate><Source id="646009" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023357">Lung Biotechnology Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="260">Peripheral vascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-27T00:00:00.000Z</StatusDate><Source id="778492" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023357">Lung Biotechnology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="260">Peripheral vascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-27T00:00:00.000Z</StatusDate><Source id="778492" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20406">Toray Industries Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="260">Peripheral vascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-03-12T00:00:00.000Z</StatusDate><Source id="530382" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023357">Lung Biotechnology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-01-27T00:00:00.000Z</StatusDate><Source id="979320" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-05T00:00:00.000Z</StatusDate><Source id="1581429" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20406">Toray Industries Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3137">Spinal stenosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-06-30T00:00:00.000Z</StatusDate><Source id="1229604" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17633">Kaken Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3137">Spinal stenosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-06-30T00:00:00.000Z</StatusDate><Source id="1229604" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20406">Toray Industries Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-05T00:00:00.000Z</StatusDate><Source id="1044562" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-08T00:00:00.000Z</StatusDate><Source id="1289192" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-06-02T00:00:00.000Z</StatusDate><Source id="1581424" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20406">Toray Industries Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-05T00:00:00.000Z</StatusDate><Source id="1044562" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-05T00:00:00.000Z</StatusDate><Source id="1044562" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-05T00:00:00.000Z</StatusDate><Source id="1044562" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20406">Toray Industries Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-06-02T00:00:00.000Z</StatusDate><Source id="1581424" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20406">Toray Industries Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="69">Renal failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-03-08T00:00:00.000Z</StatusDate><Source id="1289192" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20406">Toray Industries Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="260">Peripheral vascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-06-30T00:00:00.000Z</StatusDate><Source id="555605" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25439">United Therapeutics Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="260">Peripheral vascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-06-30T00:00:00.000Z</StatusDate><Source id="555605" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25439">United Therapeutics Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="260">Peripheral vascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-06-30T00:00:00.000Z</StatusDate><Source id="555605" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25439">United Therapeutics Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="260">Peripheral vascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-12-31T00:00:00.000Z</StatusDate><Source id="412483" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20406">Toray Industries Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-09-23T00:00:00.000Z</StatusDate><Source id="842148" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20406">Toray Industries Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-10-19T00:00:00.000Z</StatusDate><Source id="842148" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25439">United Therapeutics Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="260">Peripheral vascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-12-31T00:00:00.000Z</StatusDate><Source id="412483" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20406">Toray Industries Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-02-29T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1023357">Lung Biotechnology Inc</OwnerCompany><Country id="US">US</Country><Indication id="1867">Pulmonary hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-12-22T00:00:00.000Z</MileStoneDate><Source id="1264403" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20406">Toray Industries Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-07-10T00:00:00.000Z</MileStoneDate><Source id="943143" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20406">Toray Industries Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-05-14T00:00:00.000Z</MileStoneDate><Source id="907761" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1023357">Lung Biotechnology Inc</OwnerCompany><Country id="US">US</Country><Indication id="1867">Pulmonary hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-04-29T00:00:00.000Z</MileStoneDate><Source id="1264403" type="CORPORATE"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01609"><Name>Prostanoid receptor</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="17633">Kaken Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20406">Toray Industries Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="25439">United Therapeutics Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1c3cccc(c3O2)CCCC(=O)[O-])O)O.[Na+]</Smiles><Smiles>CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1c3cccc(c3O2)CCCC(=O)O)O)O</Smiles></StructureSmiles><Deals><Deal id="108589" title="Astellas to develop Toray's beraprost for renal disease in Japan "></Deal><Deal id="110476" title="Toray and Astellas to comarket Careload LA for PAH in Japan  "></Deal><Deal id="112370" title="Kaken Pharmaceuticals to market a oral sustained release formulation of Toray's beraprost in Japan "></Deal><Deal id="112372" title="United Therapeutics to market Toray's beraprost in North America and the US"></Deal></Deals><PatentFamilies><PatentFamily id="1808330" number="WO-00067748" title="Agents for the treatment of kidney disorders comprising 4,8-inter-m-phenylene prostaglandin I2 derivatives"></PatentFamily><PatentFamily id="2523936" number="JP-2000355541" title="Anti-tumor agent"></PatentFamily><PatentFamily id="318882" number="JP-11130678" title="The neuropathy improving agent by the neurothlipsis"></PatentFamily><PatentFamily id="497681" number="WO-09307876" title="Remedy for hepatic disease."></PatentFamily><PatentFamily id="865189" number="WO-09841210" title="Sustained-release prostaglandin I derivative preparation."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astellas Pharma Inc" id="1013295"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kaken Pharmaceutical Co Ltd" id="17633"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Toray Industries Inc" id="20406"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="United Therapeutics Corp" id="25439"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>